GLP1R and inflammatory bowel disease: Anderson et al. conducted a retrospective analysis of 120 IBD patients treated with GLP-1 receptor agonists and found a significant reduction in CRP levels over one year (12.92 vs. 6.38 mg/dL, p = 0.005) [35], however, there were no observed differences in IBD-related hospitalizations, clinical disease activity (measured by the Harvey–Bradshaw Index or Modified Mayo Score), or endoscopic scores between the year before and after treatment with GLP-1RAs.